- Home
- PRT vs TARA Comparison
PRT vs TARA Comparison
Compare PRT & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- TARA
- Stock Information
- Founded
- PRT 2017
- TARA N/A
- Country
- PRT United States
- TARA United States
- Employees
- PRT N/A
- TARA N/A
- Industry
- PRT Oil & Gas Production
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRT Energy
- TARA Health Care
- Exchange
- PRT Nasdaq
- TARA Nasdaq
- Market Cap
- PRT 45.4M
- TARA 52.4M
- IPO Year
- PRT N/A
- TARA N/A
- Fundamental
- Price
- PRT $3.37
- TARA $5.04
- Analyst Decision
- PRT
- TARA Strong Buy
- Analyst Count
- PRT 0
- TARA 3
- Target Price
- PRT N/A
- TARA $22.67
- AVG Volume (30 Days)
- PRT 51.1K
- TARA 6.6M
- Earning Date
- PRT 11-13-2024
- TARA 11-12-2024
- Dividend Yield
- PRT 11.61%
- TARA N/A
- EPS Growth
- PRT N/A
- TARA N/A
- EPS
- PRT 0.42
- TARA N/A
- Revenue
- PRT $6,059,380.00
- TARA N/A
- Revenue This Year
- PRT N/A
- TARA N/A
- Revenue Next Year
- PRT N/A
- TARA N/A
- P/E Ratio
- PRT $8.58
- TARA N/A
- Revenue Growth
- PRT N/A
- TARA N/A
- 52 Week Low
- PRT $3.41
- TARA $1.60
- 52 Week High
- PRT $5.03
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- PRT 36.42
- TARA 63.59
- Support Level
- PRT $3.41
- TARA $5.27
- Resistance Level
- PRT $4.05
- TARA $6.39
- Average True Range (ATR)
- PRT 0.14
- TARA 0.89
- MACD
- PRT -0.03
- TARA 0.05
- Stochastic Oscillator
- PRT 26.82
- TARA 36.25
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive 80% of the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).